Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 8, 2010, Pages 1420-1428

  Adler, Sharon G ^a   Schwartz, Sherwyn ^b   Williams, Mark E ^c   Arauz Pacheco, Carlos ^d   Bolton, Warren K ^e   Lee, Tyson ^f   Li, Dongxia ^f   Neff, Thomas B ^f   Urquilla, Pedro R ^f   Sewell, K Lea ^f  

^a LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b Diabetes and Glandular Disease Clinic   (United States)

^c Joslin Clinic   (United States)

^d RADIANT RESEARCH   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f FIBROGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FG 3019; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ANEMIA; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; FLUSHING; FOLLOW UP; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MAXIMUM PLASMA CONCENTRATION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SORE THROAT; THERAPY EFFECT; TUBULAR DYSFUNCTION; URINE LEVEL;

ADULT; AGED; ALBUMINURIA; ANTIBODIES, MONOCLONAL; CONNECTIVE TISSUE GROWTH FACTOR; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; KIDNEY TUBULES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77955743198     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09321209     Document Type: Article

References (49)

1. U.S. Renal Data System: USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006
2. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 865-869, 2001
3. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
4. Ruggenenti P, Pagano E, Tammuzzo L, Benini R, Garattini L, Remuzzi G: Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int 59: 286-294, 2001
5. Wahab NA, Schaefer L, Weston BS, Yiannikouris O, Wright A, Babelova A, Schaefer R, Mason RM: Glomerular expression of thrombospondin-1, TGF-beta and CTGF at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetalogica 48: 2650-2660, 2005
6. Roestenberg P, van Nieuwenhoven FA, Joles JA, Trischberger C, Martens PP, Oliver N, Aten J, Hoppener JW, Goldschmeding R: Temporal expression profile and distribution pattern indicate a role of CTGF/CCN-2 in diabetic nephropathy in mice. Am J Physiol Renal Physiol 290: F1344-F1354, 2006
7. Keil A, Blom IE, Goldschmeding R, Rupprecht HD: Nitric oxide down-regulates CTGF in rat mesangial cells. Kidney Int 62: 401-411, 2002
8. Hishikawa K, Oemar BS, Nakaki T: Static pressure regulates CTGF expression in human mesangial cells. J Biol Chem 276: 16797-16803, 2001
9. Wahab NA, Weston BS, Mason RM: Modulation of the TGFbeta/Smad signaling pathway in mesangial cells by CTGF/CCN2. Exp Cell Res 307: 305-314, 2005
10. Han KH, Kang YS, Han SY, Jee YH, Lee MH, Han JY, Kim HK, Kim YS, Cha DR: Spironolactone ameliorates renal injury and CTGF expression in type II diabetic rats. Kidney Int 70: 111-120, 2006
11. Sohn M, Tan Y, Wang B, Klein RL, Trojanowska M, Jaffa AA: Mechanisms of LDL-induced expression of CTGF in human aortic endothelial cells. Am J Physiol Heart Circ Physiol 290: H1624-H1634, 2006
12. Finckenberg P, Inkinen K, Ahonen J, Merasto S, Louhelainen M, Vapaatalo H, Muller D, Ganten D, Luft F, Mervaala E: Angiotensin II induces CTGF gene expression via calcineurin-dependent pathways. Am J Pathol 163: 355-366, 2003
13. Rodriguez-Vita J, Ruiz-Ortega M, Ruperez M, Esteban V, Sanchez-Lopez E, Plaza JJ, Egido J: Endothelin-1, via ETA and independently of TGFbeta, increases the CTGF in vascular smooth muscle cells. Circ Res 97: 125-134, 2005
14. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M: Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a TGFbeta-independent mechanism. Circ Res 111: 2509-2517, 2005 (Pubitemid 40696140)
15. Igarashi A, Okochi H, Bradham DM, Grotendorst GR: Regulation of CTGF gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 4: 637-645, 1993
16. Graness A, Cicha I, Goppelt-Streube M: Contribution of Src-FAK signaling to the induction of connective tissue growth factor in renal fibroblasts. Kidney Int 69: 1341-1349, 2006
17. Lam S, van der Geest RN, Verhagen NA, Van Nieuwenhoven FA, Blom IE, Aten J, Goldschmeding R, Daha MR, van Kooten C: CTGF and IGF-I are produced by human renal fibroblasts and cooperate in the induction of collagen production by high glucose. Diabetes 52: 2975-2983, 2003
18. Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P: CTGF plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: Implications for diabetic renal disease. J Am Soc Nephrol 17: 2484-2494, 2006
19. Kobayashi T, Inoue T, Okada H, Kikuta T, Kanno Y, Nishida T, Takigawa M, Sugaya T, Suzuki H: CTGF mediates the profibrotic effects of TGF-beta produced by tubular epithelial cells in response to high glucose. Clin Exp Nephrol 9: 114-121, 2005
20. Twigg SM, Joly AH, Chen MM, Tsubaki J, Kim HS, Hwa V, Oh Y, Rosenfeld RG: CTGF/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinol 143: 1260-1269, 2002
21. Chaqour B, Goppelt-Struebe M: Mechanical regulation of the Cyr61/CCN1 and CTGF/CCN2 proteins. Implications in mechanical stress-associated pathologies. FEBS J 273: 3639-3649, 2006
22. Liu BC, Sun J, Chen Q, Ma KL, Ruan XZ, Phillips AO: Role of CTGF in mediating hypertrophy of human proximal tubular cells induced by angiotensin II. Am J Nephrol 23: 429-437, 2003
23. Andersen S, van Nieuwenhoven FA, Tarnow L, Rossing P, Rossing K, Wieten L, Goldschmeding R, Parving HH: Reduction of urinary CTGF by Losartan in type 1 patients with diabetic nephropathy. Kidney Int 67: 2325-2329, 2005
24. Higgins DF, Biju MP, Akai Y, Wutz A, Johnson RS, Haase VH: Hypoxic induction of CTGF is directly mediated by Hif-1. Am J Renal Physiol 287: F1223-F1232, 2004
25. van Nieuwenhoven FA, Jensen LJN, Flyvbjerg A, Goldschmeding R: Imbalance of growth factor signalling in diabetic kidney disease: Is CTGF (CCN2) the perfect intervention point? Nephrol Dial Transplant 20: 6-10, 2005
26. Liu Y: Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69: 213-217, 2006
27. Abreu JG, Ketpura NI, Reversade B, De Robertis EM: CTGF modulates cell signaling by BMP and TGF-beta. Nat Cell Biol 4: 599-604, 2002
28. Nguyen TQ, Roestenberg P, van Nieuwenhoven FA, Bovenschen N, Li Z, Xu L, Oliver N, Aten J, Joles JA, Vial C, Brandan E, Lyons KM, Goldschmeding R: CTGF inhibits BMP-7 signaling in diabetic nephropathy. J Am Soc Nephrol 19: 2098-2107, 2008
29. Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, Okada Y: Matrix metalloproteinases cleave CTGF and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem 277: 36288-36295, 2002
30. Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K, Ikeda E, Takata S, Kobayashi K, Okada Y: CTGF binds VEGF and inhibits VEGF-induced angiogenesis. FASEB J 16: 219-221, 2002
31. Gilbert RE, Akdeniz A, Weitz S, Usinger WR, Molineaux C, Jones SE, Langham RG, Jerums G: Urinary CTGF excretion in patients with type 1 diabetes and nephropathy. Diabetes Care 26: 2632-2636, 2003
32. Nguyen TQ, Tarnow L, Andersen S, Hovind P, Parving HH, Goldschmeding R, Van Nieuwenhoven FA: Urinary CTGF excretion correlates with clinical markers of renal disease in a large population of type I diabetic patients with diabetic nephropathy. Diabetes Care 29: 83-88, 2006
33. Roestenberg P, van Nieuwenhoven FA, Wieten L, Boer P, Diekman T, Tiller AM, Wiersinga WM, Oliver N, Usinger W, Weitz S, Schlingemann RO, Goldschmeding R: CTGF is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 27: 1164-1170, 2004
34. Jaffa AA, Weitz S, Zheng D, Usinger WR, Garvey WT: CTGF N fragment: A maker of progressive diabetic nephropathy [Abstract]. J Am Soc Nephrol 13: 249, 2002
35. Jaffa AA, Usinger WR, McHenry B, Jaffa MA, Lipstiz SR, Lackland D, Lopes-Virella M, Luttrell LM, Wilson PW: Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab 93: 1893-1900, 2008
36. Nguyen TQ, Tarnow L, Jorsal A, Oliver N, Roestenberg P, Ito Y, Parving HH, Rossing P, Van Nieuwenhoven FA, Goldschmeding R: Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 31: 1177-1182, Jun 2008
37. Adler SG, Kang SW, Feld S, Cha DR, Barba L, Striker L, Striker G, Riser BL, LaPage J, Nast CC: Glomerular mRNAs in human type 1 diabetes: Biochemical evidence for microalbuminuria as a manifestation of diabetic nephropathy. Kidney Int 60: 2330-2336, 2001
38. Adler SG, Kang SW, Feld S, Cha DR, Barba L, Striker L, Striker G, Riser BL, LaPage J, Nast CC: Can glomerular mRNAs in human type 1 diabetes be used to predict transition from normoalbuminuria to microalbuminuria? Am J Kidney Dis 40: 184-188, 2002
39. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R: Expression of CTGF in human renal fibrosis. Kidney Int 53: 853-861, 1998
40. Flyvbjerg A, Khatir D, Jensen LJN, Lomongsod E, Liu DY, Rasch R, Usinger WR: Long-term renal effects of a neutralizing CTGF-antibody in obese type 2 diabetic mice [Abstract]. J Am Soc Nephrol 15: 261A, 2004
41. Langsetmo I, Jacob CT, Nichols B, Zhang W, Oliver N, Liu DY: Anti-CTGF therapy with FG-3019 prevents diabetes-induced cardiovascular complications in streptozotocin treated rats [Abstract]. J Am Soc Nephrol 16: 199A, 2005
42. Langsetmo I, Jacob CT, Zhang W, Oliver N, Lin A, Coker G, Liu DY: Anti-CTGF human antibody therapy with FG-3019 prevents and reverses diabetes-induced cardiovascular complications in streptozotocin treated rats. Diabetes 55[Suppl 1]: A122, 2006
43. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999
44. Rachfal AW, Brigstock DR: Structural and functional properties of CCN proteins. Vitam Horm 70: 69-103, 2005
45. Mageto Y, Flaherty K, Brown K, Fong A, Raghu G: Safety and tolerability of human monoclonal antibody FG-3019, anticonnective tissue growth factor, in patients with idiopathic pulmonary fibrosis [Abstract]. Chest 126: 7735-a, 2004
46. Tam FW, Riser BL, Meeran K, Rambow J, Pusey CD, Frankel AH: Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine 47: 37-42, 2009
47. Yokoi H, Mukoyama M, Mori K, Kasahara M, Suganami T, Sawai K, Yoshioka T, Saito Y, Ogawa Y, Kuwabara T, Sugawara A, Nakao K: Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int 73: 446-455, 2008
48. Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K, Yoshioka T, Koshikawa M, Nishida T, Takigawa M, Sugawara A, Nakao K: Reduction in connective tissue growth factor by antisense treatment meliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 15: 1430-1440, 2004
49. Guha M, Xu ZG, Tung D, Lanting L, Natarajan R: Specific down- regulation of CTGF attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 21: 3355-3368, 2007 (Pubitemid 47565554)